## Management of Locally Advanced Rectal Cancer ### Clinical Context This patient has a cT3N1M0 rectal adenocarcinoma — locally advanced disease with nodal involvement but no distant metastases. The tumour is within 6 cm of the anal verge, placing it in the lower rectum. ### Standard of Care: Neoadjuvant Chemoradiotherapy **Key Point:** For locally advanced rectal cancer (cT3–T4 or node-positive disease), neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the standard of care in India and internationally [cite:NCCN Rectal Cancer Guidelines 2023], [cite:ESMO Rectal Cancer Guidelines 2020]. ### Rationale for Neoadjuvant Approach 1. **Downstaging effect**: nCRT reduces tumour volume and improves resectability, allowing sphincter-preserving surgery when feasible. 2. **Improved local control**: Reduces local recurrence risk from ~25% to ~10%. 3. **Better toxicity profile**: Systemic chemotherapy toxicity is lower when given concurrently with radiotherapy preoperatively than postoperatively. 4. **Pathological response**: Allows assessment of treatment response (complete pathological response in ~15–20% of patients). ### Timeline - **nCRT duration**: 5–6 weeks (45–50.4 Gy in 25–28 fractions + concurrent 5-FU or capecitabine). - **Surgery timing**: 6–8 weeks after completion of nCRT to allow maximum tumour regression and tissue healing. - **Adjuvant chemotherapy**: 4 cycles of 5-FU or capecitabine + oxaliplatin after surgery if not given during nCRT. **High-Yield:** The acronym **nCRT → Surgery → Adjuvant** is the trimodal sequence for locally advanced rectal cancer. ### Expected Outcome After nCRT, reassessment imaging (MRI or CT) and clinical examination guide surgical planning. Many patients become candidates for low anterior resection (LAR) with total mesorectal excision (TME) rather than abdominoperineal resection (APR).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.